Mezgebe Berhe

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink et al. · New England Journal of Medicine · 2022 · 270 citations · Full text

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Cameron R. Wolfe, Kay M Tomashek, Thomas F. Patterson et al. · The Lancet Respiratory Medicine · 2022 · 127 citations · Full text

Long Covid, Clinical Therapeutic, Covid-19 Pandemic +6

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Thomas L Holland, Adit A. Ginde, Roger Paredes et al. · The Lancet Respiratory Medicine · 2022 · 124 citations · Full text

Covid-19 Pandemic, Antiviral Therapy, Clinical Trials +3

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot et al. · The Lancet HIV · 2022 · 96 citations

Treatment And Prevention, Initial Treatment, Clinical Trials +6